These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
166 related items for PubMed ID: 28493496
21. From structure--based to knowledge--based drug design through x-ray protein crystallography: sketching glycogen phosphorylase binding sites. Chrysina ED, Chajistamatiou A, Chegkazi M. Curr Med Chem; 2011; 18(17):2620-9. PubMed ID: 21568887 [Abstract] [Full Text] [Related]
22. New synthesis of 3-(β-D-glucopyranosyl)-5-substituted-1,2,4-triazoles, nanomolar inhibitors of glycogen phosphorylase. Kun S, Bokor É, Varga G, Szőcs B, Páhi A, Czifrák K, Tóth M, Juhász L, Docsa T, Gergely P, Somsák L. Eur J Med Chem; 2014 Apr 09; 76():567-79. PubMed ID: 24608000 [Abstract] [Full Text] [Related]
23. Synthesis of N-glucopyranosidic derivatives as potential inhibitors that bind at the catalytic site of glycogen phosphorylase. Gimisis T. Mini Rev Med Chem; 2010 Oct 09; 10(12):1127-38. PubMed ID: 20716054 [Abstract] [Full Text] [Related]
24. Structure-activity analysis of the purine binding site of human liver glycogen phosphorylase. Ekstrom JL, Pauly TA, Carty MD, Soeller WC, Culp J, Danley DE, Hoover DJ, Treadway JL, Gibbs EM, Fletterick RJ, Day YS, Myszka DG, Rath VL. Chem Biol; 2002 Aug 09; 9(8):915-24. PubMed ID: 12204691 [Abstract] [Full Text] [Related]
25. The prototype of glycogen phosphorylase. Chrysina ED. Mini Rev Med Chem; 2010 Oct 09; 10(12):1093-101. PubMed ID: 20716055 [Abstract] [Full Text] [Related]
26. Ternary complex crystal structures of glycogen phosphorylase with the transition state analogue nojirimycin tetrazole and phosphate in the T and R states. Mitchell EP, Withers SG, Ermert P, Vasella AT, Garman EF, Oikonomakos NG, Johnson LN. Biochemistry; 1996 Jun 11; 35(23):7341-55. PubMed ID: 8652510 [Abstract] [Full Text] [Related]
27. 3'-axial CH2 OH substitution on glucopyranose does not increase glycogen phosphorylase inhibitory potency. QM/MM-PBSA calculations suggest why. Manta S, Xipnitou A, Kiritsis C, Kantsadi AL, Hayes JM, Skamnaki VT, Lamprakis C, Kontou M, Zoumpoulakis P, Zographos SE, Leonidas DD, Komiotis D. Chem Biol Drug Des; 2012 May 11; 79(5):663-73. PubMed ID: 22296957 [Abstract] [Full Text] [Related]
34. 5-Chloroindoloyl glycine amide inhibitors of glycogen phosphorylase: synthesis, in vitro, in vivo, and X-ray crystallographic characterization. Wright SW, Rath VL, Genereux PE, Hageman DL, Levy CB, McClure LD, McCoid SC, McPherson RK, Schelhorn TM, Wilder DE, Zavadoski WJ, Gibbs EM, Treadway JL. Bioorg Med Chem Lett; 2005 Jan 17; 15(2):459-65. PubMed ID: 15603973 [Abstract] [Full Text] [Related]
35. A new allosteric site in glycogen phosphorylase b as a target for drug interactions. Oikonomakos NG, Skamnaki VT, Tsitsanou KE, Gavalas NG, Johnson LN. Structure; 2000 Jun 15; 8(6):575-84. PubMed ID: 10873856 [Abstract] [Full Text] [Related]
36. Inhibition of glycogen phosphorylase in the context of type 2 diabetes, with focus on recent inhibitors bound at the active site. Praly JP, Vidal S. Mini Rev Med Chem; 2010 Oct 15; 10(12):1102-26. PubMed ID: 20716051 [Abstract] [Full Text] [Related]